A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs

Biochemical and Biophysical Research Communications

Volumn 429, Issue 1-2, 2012, Pages 51-56

  Fujisaki, Seiichiro ^a   Takashita, Emi ^a   Yokoyama, Masaru ^a   Taniwaki, Tae ^b   Xu, Hong ^a   Kishida, Noriko ^a   Sato, Hironori ^a   Tashiro, Masato ^a   Imai, Masaki ^a   Odagiri, Takato ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Kochi Public Health and Sanitation Institute   (Japan)

Author keywords

3D structure; Influenza B virus; Neuraminidase inhibitor resistant; Novel mutation in influenza B virus neuraminidase

Indexed keywords

LANINAMIVIR; MONOMER; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; TETRAMER; VIRUS SIALIDASE; ZANAMIVIR;

ADULT; ANIMAL CELL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CASE REPORT; CELL STRAIN; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; INFLUENZA B; INFLUENZA VIRUS B; MALE; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; VIRUS DETECTION; VIRUS MUTANT; VIRUS MUTATION;

ANIMALS; ANTIVIRAL AGENTS; CATALYTIC DOMAIN; CYCLOPENTANES; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HEK293 CELLS; HUMANS; INFLUENZA B VIRUS; MADIN DARBY CANINE KIDNEY CELLS; MODELS, MOLECULAR; MUTATION; NEURAMINIDASE; OSELTAMIVIR; PROTEIN CONFORMATION; VIRAL PROTEINS; ZANAMIVIR;

INFLUENZA B VIRUS; ORTHOMYXOVIRIDAE;

EID: 84870390549     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.10.095     Document Type: Article

References (42)

1. Cady S.D., Mishanina T.V., Hong M. Structure of amantadine-bound M2 transmembrane peptide of influenza A in lipid bilayers from magic-angle-spinning solid-state NMR: the role of Ser31 in amantadine binding. J. Mol. Biol. 2009, 385:1127-1141.
2. Schnell J.R., Chou J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008, 451:591-595.
3. Mould J.A., Paterson R.G., Takeda M., Ohigashi Y., Venkataraman P., Lamb R.A., et al. Influenza B virus BM2 protein has ion channel activity that conducts protons across membranes. Dev. Cell. 2003, 5:175-184.
4. Palese P., Tobita K., Ueda M., Compans R.W. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
5. Liu C., Eichelberger M.C., Compans R.W., Air G.M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 1995, 69:1099-1106.
6. Bossart-Whitaker P., Carson M., Babu Y.S., Smith C.D., Laver W.G., Air G.M. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J. Mol. Biol. 1993, 232:1069-1083.
7. Varghese J.N., McKimm-Breschkin J.L., Caldwell J.B., Kortt A.A., Colman P.M. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992, 14:327-332.
8. Varghese J.N., Epa V.C., Colman P.M. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci. 1995, 4:1081-1087.
9. Shetty A., Peek L.A. Peramivir for the treatment of influenza. Expert Rev. Anti. Infect. Ther. 2012, 10:123-143.
10. Vavricka C.J., Li Q., Wu Y., Qi J., Wang M., Liu Y., et al. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog. 2011, 7:e1002249.
11. Burmeister W.P., Ruigrok R.W., Cusack S. The 2.2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J. 1992, 11:49-56.
12. Oakley A.J., Barrett S., Peat T.S., Newman J., Streltsov V.A., Waddington L., et al. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J. Med. Chem. 2010, 53:6421-6431.
13. Tashiro M., McKimm-Breschkin J.L., Saito T., Klimov A., Macken C., Zambon M., et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir. Ther. 2009, 14:751-761.
14. Gubareva L.V., Matrosovich M.N., Brenner M.K., Bethell R.C., Webster R.G. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J. Infect. Dis. 1998, 178:1257-1262.
15. Mishin V.P., Hayden F.G., Gubareva L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 2005, 49:4515-4520.
16. Hurt A.C., Iannello P., Jachno K., Komadina N., Hampson A.W., Barr I.G., et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob. Agents Chemother. 2006, 50:1872-1874.
17. Hatakeyama S., Sugaya N., Ito M., Yamazaki M., Ichikawa M., Kimura K., et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA, J. Am. Med. Assoc. 2007, 297:1435-1442.
18. Carr S., Ilyushina N.A., Franks J., Adderson E.E., Caniza M., Govorkova E.A., et al. Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer. Pediatr. Infect. Dis. J. 2011, 30:284-288.
19. Ujike M., Shimabukuro K., Mochizuki K., Obuchi M., Kageyama T., Shirakura M., et al. Oseltamivir-resistant influenza viruses A (H1N1) during 2007-2009 influenza seasons, Japan. Emerg. Infect. Dis. 2010, 16:926-935.
20. Neumann G., Watanabe T., Ito H., Watanabe S., Goto H., Gao P., et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. USA 1999, 96:9345-9350.
21. Imai M., Watanabe S., Ninomiya A., Obuchi M., Odagiri T. Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly. J. Virol. 2004, 78:11007-11015.
22. Ujike M., Ejima M., Anraku A., Shimabukuro K., Obuchi M., Kishida N. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1)2009, virus, Japan, 2009-2010. Emerg. Infect. Dis. 2011, 17:470-479.
23. Deshpande N., Addess K.J., Bluhm W.F., Merino-Ott J.C., Townsend-Merino W., Zhang Q., et al. The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res. 2005, 33:D233-D237.
24. Song H., Nakayama E.E., Yokoyama M., Sato H., Levy J.A., Shioda T. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J. Virol. 2007, 81:7280-7285.
25. Shirakawa K., Takaori-Kondo A., Yokoyama M., Izumi T., Matsui M., Io K., et al. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol. 2008, 15:1184-1191.
26. Labute P. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 2008, I:1693-1698.
27. Ponder J.W., Case D.A. Force fields for protein simulations. Adv. Protein Chem. 2003, 66:27-85.
28. Onufriev A., Bashford D., Case D.A. Modification of the generalized Born model suitable for macromolecules. J. Phys. Chem. B 2000, 104:3712-3720.
29. Hurt A.C., Holien J.K., Parker M., Kelso A., Barr I.G. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J. Virol. 2009, 83:10366-10373.
30. Yen H.-L., Hoffmann E., Taylor G., Scholtissek C., Monto A.S., Webster R.G., et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J. Virol. 2006, 80:8787-8795.
31. Bastien N., Gubbay J.B., Richardson D., Sleeman K., Gubareva L., Li Y. Detection of an influenza B virus strain with reduced susceptibility to neuraminidase inhibitor drugs. J. Clin. Microbiol. 2011, 49:4020-4021.
32. Ode H., Ota M., Neya S., Hata M., Sugiura W., Hoshino T. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 2005, 109:565-574.
33. Ode H., Neya S., Hata M., Sugiura W., Hoshino T. Computational simulations of HIV-1 proteases-multi-drug resistance due to nonactive site mutation L90M. J. Am. Chem. Soc. 2006, 128:7887-7895.
34. Ode H., Matsuyama S., Hata M., Hoshino T., Kakizawa J., Sugiura W. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations. J. Med. Chem. 2007, 50:1768-1777.
35. Chen J., Zhang S., Liu X., Zhang Q. Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: free energy calculation and molecular dynamic simulation. J. Mol. Model. 2010, 16:459-468.
36. Nicholson L.K., Yamazaki T., Torchia D.A., Grzesiek S., Bax A., Stahl S.J., et al. Flexibility and function in HIV-1 protease. Nat. Struct. Biol. 1995, 2:274-280.
37. Lu H.P., Xun L., Xie X.S. Single-molecule enzymatic dynamics. Science 1998, 282:1877-1882.
38. Eisenmesser E.Z., Millet O., Labeikovsky W., Korzhnev D.M., Wolf-Watz M., Bosco D.A., et al. Intrinsic dynamics of an enzyme underlies catalysis. Nature 2005, 438:117-121.
39. Henzler-Wildman K.A., Lei M., Thai V., Kerns S.J., Karplus M., Kern D. A hierarchy of timescales in protein dynamics is linked to enzyme catalysis. Nature 2007, 450:913-916.
40. Abbondanzieri E.A., Bokinsky G., Rausch J.W., Zhang J.X., Le Grice S.F.J., Zhuang X. Dynamic binding orientations direct activity of HIV reverse transcriptase. Nature 2008, 453:184-189.
41. Astumian R.D. Thermodynamics and kinetics of a Brownian motor. Science 1997, 276:917-922.
42. Thorpe I.F., Brooks C.L. Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. USA 2007, 104:8821-8826.